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Pain Perception in Depression: Relationships to Symptomatology and 
Naloxone-Sensitive Mechanisms 
STEFAN LAUTENBACHER, PHD, STEPHAN RoscHER, DoMINIK STRIAN, 
KLAUS F ASSBENDER, MD, KLAUS KRUMREY, AND JÜRGEN-CHRISTIAN KRIEG, MD 
A decrease in pain sensitivity during acute depression has been observed in several studies, apparently 
related to the severity of symptomatology. However, the question remains whether this relationship can be 
found only in heterogeneous groups of depressive patients or also in a single diagnostic group, such as major 
depression. In the present study, pain thresholds were assessed in 20 patients with major depression (DSM-
III-R) and in 20 healthy controls. Two threshold methods with a differing impact of reaction time on the 
results were used. Contact heat was applied as a natural source of pain. With both methods the pain 
thresholds were significantly increased in the depressive patients. No relationship was found to the various 
symptoms of depression assessed by psychopathometric scales. In contrast to the pain thresholds, the 
thresholds of skin sensitivity for nonnoxious stimuli (warmth, cold, vibration) were only slightly increased. 
In subsamples (N = 10 in each group), naloxone (5 mg IV) and placebo were administered in a double-blind 
design. No systematic changes in pain thresholds occurred under either treatment. Our findings suggest that 
the decrease in skin sensitivity in major depression is specific to pain and not due to an increased reaction 
time. Moreover, the decrease appears to be related neither to a naloxone-sensitive mechanism nor to 
symptomatology. 
Key words: major depression, pain perception, somatosensation, naloxone. 
INTRODUCTION 
Depression and pain appear to be closely related. 
This view stems mainly from research that investi-
gates the mutual influences of depression and 
chronic pain (1). On the one hand, depression con-
stitutes a state of increased vulnerability to pain 
problems and changes the way one deals with them 
(2, 3). On the other hand, chronic pain is frequently 
accompanied by depressive symptoms, and it some-
times leads to a full-blown depressive disorder 
(4, 5). 
But, depression also has another relationship to 
the pain system: It seems to reduce pain sensitivity. 
(Previous studies of this relationship are cited later 
on.) Hence, the influence of depression on the pain 
system appears tobe somewhat paradoxical because 
both an increase in clinical pain problems and a 
decrease in experimental pain sensitivity have been 
observed. 
Hall and Stride (6) reported as early as 1954 on an 
increased pain threshold for radiation heat in de-
pressive patients. This phenomenon was especially 
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distinct in patients with endogenous depression. The 
authors considered two types of causation. First, 
depression might represent a general state of percep-
tual unresponsiveness, with diminished pain per-
ception being only one example. Second, depression 
might produce an affective indifference to aversive 
stimulation that is not based on a truly sensory 
deficit. 
lt now seems unlikely that there is a generalized 
perceptual unresponsiveness; von Knorring (7, 8) 
found no difference between depressive patients and 
healthy controls for the electrical detection thresh-
old but did find a significant difference for the pain 
threshold, suggesting that the effect of depression is 
specific to pain. In support of an affective indiffer-
ence as the cause, Ben-Tovim and Schwartz (9) 
observed that in a group of depressive patients only 
those with the symptom "emotional indifference" 
had increased electrical pain thresholds. Further-
more, Davis et al. (10), using electrical stimulation 
and signal detection analysis of the results, provided 
some evidence that stoic responses, rather than a 
sensory deficit, underlies the pain insensitivity in 
depression. Their results seem to corroborate the 
"emotional indifference" hypothesis. However, 
there have also been other outcomes with the signal 
detection approach (11, 12), and a too straightfor-
ward interpretation of the signal detection parame-
ters as reflecting the sensory and affective compo-
nents of the pain response may be misleading (13). 
Currently, it has seemed highly likely that the 
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degree of illness severity and the type of symptom-
atology are major influences, as suggested by the 
findings of Hall and Stride (6). Von Knorring (8) 
demonstrated that patients with psychotic symp-
toms had higher electrical pain and tolerance 
thresholds than those without. He and other authors 
found that patients with psychomotor retardation 
were less pain sensitive than agitated patients (7, 
14). Otto et al. (15) did not find a change in experi-
mental pain parameters in their study of mild forms 
of depression. Furthermore, Hall and Stride (6) and 
von Knorring (16) reported normalized pain sensitiv-
ity in individuals who had recovered from depres-
sion. 
The perceptual deficit has appeared to be specific 
to pain and dependent on symptomatology. One 
shortcoming of the studies conducted so far has been 
that the diagnostic procedures either were not de-
scribed explicitly or did not correspond to contem-
porary norms. Therefore, one aim of the present 
investigation was to study the relationship between 
pain sensitivity and illness severity in a clearly 
defined group, in this case patients diagnosed as 
having major depression according to DSM-III-R (17). 
Another problem with past studies has been the 
choice of the stimulation methods used. Electrocu-
taneous stimulation was applied in most of the stud-
ies (7-10, 14, 16), which leads to artificial pain sen-
sations and therefore might not be fully suitable for 
the study of psychiatric patients. The importance of 
this methodological issue is especially evident if we 
look at a study clone by Merskey (18). Merskey used 
a pressure algometer and found, in contrast to the 
authors just cited, that healthy controls had higher 
pain and tolerance thresholds than depressive pa-
tients. Therefore, a study of depressive patients 
seemed in order, using a stimulation method that 
produces natural pain sensations with state-of-the-
art methodology. This led us to apply contact heat 
with a Peltier thermode (19, 20). 
An additional aim of our study was to consider 
the possible role of the perceptual processing speed. 
For this reason we used two methods to assess heat 
pain thresholds, one that is dependent on the reac-
tion time and another that is not. Moreover, some 
of the findings reported suggest that the decrease in 
pain sensitivity is not due to a generalized deficit in 
somatosensory perception. To broaden the basis for 
this conclusion, we assessed several somatosensory 
modalities (warmth, cold, vibration). 
Finally, and perhaps most important, we wanted 
to shed some light on the mechanisms of causation. 
Davis et al. (10) proposed "studies with narcotic 
antagonists in depressed pain-tolerant patients." 
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However, none of the subsequent studies has in· 
cluded this or any other pharmacological strategy of 
investigation. Although an opioidergic causation of 
depression is now, after a phase of enthusiastic spec· 
ulation, considered unlikely, the possibility ofopioid 
dysfunctions in certain spinal or cerebral systems 
has not yet been dismissed (21, 22). Considering the 
great importance of opiates and opioids for analgesic 
changes, an attempt that follows this line of reason· 
ing seemed worthwhile, at least as a first step. There· 
fore, we decided to study pain sensitivity before and 
after the administration of the opiate antagonist 
naloxone in a subsample of the depressive patients. 
METHODS 
Subjects 
The subjects were 20 patients (8 warnen and 12 rnen) with the 
DSM-III-R diagnosis of a major depression (17) and 20 healthy 
controls matched for age and sex. The patients' diagnoses were 
confirmed by the Structured Clinical Interview for DSM-Ill-R 
(23). In addition, a score ofmore than 18 on the Hamilton Depres-
sion Scale (24) was required. Subjects were excluded frorn the 
study if they suffered from an additional psychiatric disorder, an 
organic mood syndrome (e.g. due to an endocrine disorder), if 
there was evidence of a psychoactive substance use disorder, or 
if there were clinical signs of disk disease, neuropathy, hyperten-
sion, or dermatosis at the site of somatosensory stimulation. The 
patients were studied in the first 2 weeks after admission and 
before initiation of any pharmacological treatment. Six patients 
were on antidepressant medication at admission (fluvoxamine, 
doxepin, dibenzepin, clomipramine, and two on maprotiline). 
These patients underwent a 7- to 12-day washout period, the 
duration of which was at least three times the half-life of the 
respective drug and its active metabolite. Table 1 gives a descrip-
TABLE 1. Basic and Psychopathometric Description and 
Local Skin Temperature at the Site of Threshold Assessment 
of Depressive Patients and Healthy Controls (mean ± SD) 
Age 
Hamilton Depression Scale 
IMPS-PHS 
IMPS-OPS 
IMPS-DS 
IM PS-MS 
Depression Scale* 
Complaint List* 
STAl-Xl* 
Skin Ternperature ('C)** 
Depressive Patients Hea!thy Controls 
(N = 20/8 W, (N = 20/8 W, 
12 M) 12 M) 
36.9 ± 12.0 
25.1±5.0 
0.0 ± 0.0 
6.1 ± 3.6 
32.2 ± 8.0 
1.6 ± 2.5 
31.1 ±8.9 
34.5 ± 15.0 
57.7 ± 13.3 
27.7 ± 2.5 
36.2 ± 11.0 
2.2 ± 2.3 
5.6 ± 7.3 
31.7±5.9 
29.9 ± 2.7 
• p < 0.001, t test (one-tailed); ** p < 0.01, t test (two-tailed). IMPS-
PHS = IMPS-Paranoid-Hallucinatory Syndrome; IMPS-OPS = IMPS-
Other Psychotic Symptoms; IMPS-DS = IMPS-Depressive Syn-
drome; IMPS-MS = IMPS-Manic Syndrome. 
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tion of the samples. The protocol was approved by an ethics 
commission; all subjects gave written informed consent. 
Apparatus and Procedure 
The physical examination and one part of the psychopathom-
etric assessment took place 1 or 2 days before the first test session. 
The assessment included observer ratings on the Hamilton 
Depression Scale (HDS) (21-item version) (24) and on the Inpatient 
Multidimensional Psychiatrie Scale (IMPS) (25). The IMPS meas-
ures 12 basic psychopathological dimensions, which can be 
grouped into four categories to describe psychiatric syndromes 
(paranoid-hallucinatory syndrome, other psychotic symptoms, 
depressive syndrome, manic syndrome). 
All patients and controls took part in a first test session (day 
1), at the beginning of which pain sensitivity and somatosensation 
were tested under baseline conditions. Ten patients of each group 
were also subjects in a second test session on another day (day 
2), with a maximum interval of 3 days. Two test sessions were 
necessary to evaluate the effect of the opiate antagonist naloxone. 
Only a subsample was studied under pharmacological treatment 
because some patients refused to take part in two sessions, and 
for other patients a further delay in antidepressant treatment 
seemed inappropriate. 
In the subgroups with two sessions, naloxone and placebo were 
administered in a double-blind design as used in an earlier study 
(26), with neither the subjects nor the investigator knowing which 
treatment was being used. To control for order effects, the order 
of naloxone and placebo was randomized for the first half of the 
subjects in each group and then the second half were treated in 
the reverse order. 
To control for any influences of "needle stress" and the expec-
tation of receiving a pharmacological treatment, the subjects with 
only one session were given a placebo infusion after the baseline 
evaluation and took part in a "posttreatment" measurement. 
Thus, in the first session (day 1), the procedures were identical 
for all subjects. 
The sessions always started at 3:30 PM. On day 1, the following 
scales were given at the beginning of the session: Depression Scale 
(DS) (27) for the assessment of anxious-depressive mood; Com-
plaint List (CL) (27) for the assessment of somatic and general 
complaints as reported in particular by psychiatric patients; and 
the state version of the State-Trait Anxiety Inventory (STAI-Xl) 
(28). 
Then two identical blocks of measurements followed, one 
before and one after the treatment. Each block took approxi-
mately 25 minutes. After the first block, 100 ml of saline either 
with or without 5 mg of naloxone (NarcantiR) was administered 
IV. A <lose of 5 mg was chosen to block the effects of all endoge-
nous opioids; opioids binding on kappa- and delta-receptors can 
be antagonized only by considerably !arger <loses than required 
for opioids binding on mu-receptors, where amounts below 1 mg 
seem to be sufficient (29). The second block of measurements 
followed 30 minutes later. 
Each block started with the administration of eight visual 
analog scales for assessment of subjective state. The scales meas-
ured tiredness, headache, dryness of mouth, nausea, physical 
discomfort, bad mood, sensation of warmth, and drowsiness. 
The device used for the subsequent tests was the computer-
controlled stimulation unit PA TH-Tester MPI 100 (Phywe GmbH, 
Göttingen, Germany) which produces thermal stimuli by a Peltier 
thermode (stimulation area: 6 cm2; contact pressure: 0.4 N/cm 2). 
The lang edge of the thermode was attached to the right lateral 
dorsum pedis at a distance of about 1 cm from the toes. 
First, the heat pain threshold was assessed by a method that is 
to some degree dependent on reaction time [Pain Threshold 1). 
The pain threshold was determined by having the subject stop a 
temperature rise of 0.7°C/sec, starting from 38°C, as soon as s/he 
felt pain. There were eight trials. The threshold was computed as 
the mean of the peak temperatures of the last five trials. 
As indicators of thermal skin sensitivity, warmth and cold 
thresholds were measured by applying seven warm stimuli and 
then seven cold stimuli, starting from 32°C. The rate of the 
temperature change was again 0.7°C/sec. The subject had to 
press a button as soon as s/he noticed a change in temperature. 
The mean differences between the base temperature and the 
peak temperature in the two sets of seven trials were the measures 
of the warmth and cold thresholds. 
Then a second measurement of heat pain threshold was con-
ducted, using a method developed for the present study [Pain 
Threshold 2). This threshold measure was designed to be free of 
reaction time influences. The subject had to adjust the tempera-
ture to the level of her/his pain threshold with heating and 
cooling buttons, starting from 38°C. The change in temperature 
stopped when the subject released the buttons. Therefore, the 
rate of stimulation was dependent on the subject's speed of 
adjustment. Seven trials were conducted. The threshold was 
computed as the mean of the last six trials. 
Finally, as an indicator of skin sensitivity to mechanical stim-
uli, the vibration threshold was assessed by a VIBRA-Tester 
(Phywe GmbH) (30). The site of threshold determination was the 
dorsomedial aspect of the first metatarsal hone, where the stim-
ulator was fixed with a contact pressure of 3.7 N/cm2• The 
vibration amplitude was increased from zero at a rate of change 
of 0.2 µm/sec until the subject felt the vibration and pressed a 
button. There were three trials. Then, in another three trials, the 
vibration amplitude was decreased at the same rate of change 
from a clearly supra-threshold value until the sensation disap-
peared. As Claus (30) suggested, the logarithm of the average of 
the six trials multiplied by 10 was taken as the vibration thresh-
old. 
During each block skin temperature was assessed four times 
on the dorsal side of the same foot with a PT-100 sensor, and the 
average was taken. 
Evaluation 
Inspection of the measures assessed under baseline conditions 
(psychopathological and psychological measures, pain and soma-
tosensory sensitivity, and skin temperature before the treatrnent 
on day 1) led to the conclusion that the use of parametric statis-
tical methods (multivariate [MANOVA), univariate (ANOVA) 
analyses of variance t test, and Pearson correlation) was justified. 
The difference between the measures before and after the 
treatment was computed to evaluate the treatment effect. The 
sign of the difference was reversed so that a positive value of this 
change score indicates an increase of thresholds and a negative 
value a decrease. These change scores differed clearly in variance 
between the groups and the treatments. Therefore, nonparametric 
statistics were used (Wilcoxon signed-ranks lest). 
One-tailed significance tests were used when directed hy-
potheses were available, such as "higher pain and somatosensory 
thresholds as well as more psychopathology in depression," "pos-
itive relationship between disease severity and both pain and 
somatosensory thresholds," and "decrease in pain and somatosen-
sory thresho!ds under naloxone compared to placebo." In all other 
cases, two-tailed tests were applied. The alpha-level was 0.05 
throughout. 
RESULTS 
Psychopathology 
Of the 20 patients studied, all diagnosed as having 
a major depression according to DSM-III-R, two had 
rnood-congruent psychotic features. The psycho-
pathology, assessed multidimensionally, is pre-
sented in Table 1. 
The patients differed highly significantly from the 
control subjects on those scales administered to both 
groups (DS, CL, and STAI-X1). With reference to the 
normal values (25, 27, 28, 31), the patients' high 
scores on the scales HDS, IMPS-Depressive Syn-
drome, DS, CL, and ST AI-X1 and their low scores 
on the IMPS scales paranoid-hallucinatory syn-
drome, other psychotic symptoms, and manic syn-
drome indicate the presence of a moderate to severe 
depressive core syndrome but the absence of addi-
tional psychopathology. Furthermore, the patients 
appeared to be suffering from considerable levels of 
anxious-depressive mood, anxiety, and psychoso-
matic complaints. 
Group Comparisons of Pain and Somatosensory 
Thresholds 
The possible group difference in pain sensitivity 
between the depressive patients and the healthy 
controls was evaluated by a multivariate analysis of 
variance (MANOV A) with the two pain thresholds 
(Pain Threshold 1 and Pain Threshold 2) as depend-
ent variables. The group effect was significant (Ho-
telling's test, F(2, 37) = 3.2, p (one-tailed) = 0.026 ). 
The cor-
responding mean threshold values are shown in 
Figure 1. 
The univariate tests (ANOV A) conducted subse-
quently revealed that the difference was based al-
most equally on the two pain thresholds: Pain 
Threshold 1, F(1,38) = 3.0, p (one-tailed) = 0.047; 
Pain Threshold 2, F(1,38) = 6.6, p (one-tailed) = 
0.007. The contribution of Pain Threshold 2 to the 
overall difference appeared to be slightly greater, 
suggesting that the increase in pain thresholds in 
the depressive patients was definitely not due to a 
prolongation of reaction time. 
To test for a group difference in skin sensitivity 
for nonnoxious stimulation, we computed a second 
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MANOV A with the warmth, cold, and vibration 
thresholds as dependent variables. No significant 
group effect resulted (Hotelling's test, F(3, 35) = 1.6, 
p (one-tailed) = 0.102). Figure 2 shows the corre-
sponding mean threshold values and reveals just a 
trend toward higher thresholds in the depressive 
patients. 
Local skin temperature, a variable of interest 
when skin sensitivity is under investigation, differed 
highly significantly between the groups, with lower 
values for the patients (Table 1). lt is unlikely that 
this effect was caused by the room temperature 
during testing, because the temperature was about 
the same on the average in both groups (patients, 
22.1°C; controls, 21.6°C). 
For none of the variables discussed in this section 
was there a significant group difference between the 
Fig.1. 
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patients who had not been on medication at admis-
sion and those who had been on antidepressant 
medication and had experienced a washout period. 
Correlations of the Pain Thresholds With Other 
Measures (Patients Only) 
The only associations that were evaluated were 
between the two pain thresholds and (a) the meas-
ures of psychopathology and (b) the local skin tem-
perature, because the pain thresholds alone were 
elevated in the patients. Of the four IMPS syndrome 
scales, only the depressive syndrome scale had 
enough variance to allow a correlation computation. 
The three primary scales contributing to this syn-
drome scale, anxious depression (mean = 11.0, SD 
= 4.3), retardation and apathy (mean = 6.0, SD = 
3.6), and impaired functioning (mean = 15.2, SD = 
2.8), could also be included. The results are given in 
Table 2. None of the psychopathological measures 
nor the local skin temperature correlated sig-
nificantly with either of the two pain thresholds 
(Table 2). 
In the patients with major depression, the severity 
of depressive symptoms appeared to have no influ-
ence on the degree of pain threshold elevation. This 
is especially noteworthy with respect to the IMPS-
retardation and apathy scale because reduced pain 
sensitivity has been claimed to be associated with 
psychomotor retardation in depression (see "Intro-
duction"). Although the patients had both elevated 
pain thresholds and decreased local skin tempera-
ture, the relationship between these two measures 
was not strong. 
Effects of Naloxone 
The effects of naloxone and placebo were inves-
tigated in subgroups of 10 patients and 10 healthy 
controls. These subgroups did not differ from 
the other subjects with regard to the pain and so-
matosensory thresholds under baseline conditions 
(MANOVA, depressives, pain thresholds: Hotelling's 
test, F(2, 17) = 0.5, p (two-tailed) = 0.642; depres-
sives, somatosensory thresholds: Hotelling's test, 
F(3,15) = 0.8, p (two-tailed) = 0.526; controls, pain 
thresholds: Hotelling's test, F(2,17) = 2.2, p (two-
tailed) = 0.142; controls, somatosensory thresholds: 
Hotelling's test, F(3,16) = 0.9, p (two-tailed) = 0.471). 
This suggests that representative subsamples were 
obtained. 
Treatment effects were evaluated by comparing 
the change scores for the naloxone and placebo 
sessions using the Wilcoxon signed-ranks test. The 
change scores for the pain and somatosensory 
thresholds are shown in Figure 3, A and B. lt is 
obvious from the figures that the only substantial 
T ABLE 2. Pearson Correlations (R) Between Pain Thresholds 
1 and 2 and the Measures of Psychopathology and the Local 
Skin Temperature in the Depressive Patients lN = 20) 
Pain Threshold Pain Threshold 
1 2 
HDS -0.021 0.329 
IMPS-DS -0.143 0.207 
IMPS-ANX -0.250 0.197 
IMPS-RTD 0.041 0.066 
IMPS-IMP -0.074 0.199 
OS 0.191 0.267 
CL 0.218 0.192 
STAl-Xl -0.148 -0.137 
Skin Temperature -0.027 -0.251 
IMPS-DS = IMPS-Depressive Syndrome; IMPS-ANX = IMPS-Anx-
ious Depression; IMPS-RTD = IMPS-Retardation and Apathy; IMPS-
IMP = IMPS-lmpaired Functioning. 
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differences between naloxone and placebo occurred 
in the depressive patients. The change scores for the 
warmth and cold thresholds were clearly higher 
under placebo than under naloxone, which resulted 
in a significant difference for the cold threshold ( p 
(one-tailed) = 0.003) and an almost significant one 
for the warmth threshold (p (one-tailed) = 0.057). 
For none of the other somatosensory thresholds (pa-
tients: vibration threshold; control subjects: warmth, 
cold, and vibration thresholds) was there a signifi-
cant difference (p (one-tailed) > 0.05). Furthermore, 
naloxone did not affect the pain thresholds differ-
ently from placebo in either the patients or the 
controls (p (one-tailed) > 0.05, for all comparisons). 
None of the change scores for the eight visual 
analog scales measuring subjective state nor for the 
local skin temperature showed significant differ-
ences between naloxone and placebo in either group 
(p (two-tailed) > 0.05, for all comparisons). These 
variables did not seem to be the cause of the change 
in thermal thresholds. 
DISCUSSION 
The present study corroborates the findings of 
other investigators that depression produces a de-
crease in pain sensitivity. The novel aspect of our 
study is that the subjects were patients diagnosed as 
having a major depression according to the contem-
porary definition of DSM-III-R. Earlier studies ob-
served the decrease in pain sensitivity mainly in 
patients who were described as having endogenous 
depression or psychotic symptoms, and less often in 
patients with neurotic depression (6, 8, 14, 15). Thus, 
the current diagnosis of major depression, which is 
based on the duration and severity of the depressive 
symptoms and abandons the idea of a dichotomy 
between neurotic and endogenous depression, still 
identifies a group of patients with hypalgesic 
changes. 
The increase in pain thresholds was found with a 
method that uses contact heat stimulation. There-
fore, the notion that in the majority of the earlier 
studies, in which electrical skin stimulation was 
applied (7-10, 14, 16), the results were because of 
the artificial quality of the pain sensation, does not 
appear to be substantiated. Furthermore, the fact 
that similar results were obtained with two pain 
threshold measurement procedures, one in which 
the rate of stimulation was pre-set and the other in 
which the subject determined the rate, rules out the 
reaction time or, in general, the speed of perceptual 
processing as a major influence. 
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The lack of similar increases in the thresholds for 
nonnoxious skin sensitivity (warmth, cold, vibra-
tion) proves that the perceptual change is specific to 
pain. This finding is in agreement with those ob-
tained by Ben-Tovim and Schwartz (9) and by von 
Knorring (7, 8), who observed elevated electrical 
pain thresholds but almost normal electrical detec-
tion thresholds. Therefore, somatosensation seems 
to be intact, whereas pain perception is disturbed. 
This does not exclude the possibility that perceptual 
deficits exist in other sensory modalities or that 
attention is impaired. 
We used a variety of instruments measuring psy-
chopathology, including self-ratings and observer 
ratings, to assess numerous aspects of depression 
(depressive mood, functional impairment, anxiety, 
cognitive and psychomotor changes, etc.). None of 
these variables showed any relationship to the pain 
thresholds in the depressive patients. The idea, de-
rived from earlier studies (7, 8, 14), that the severity 
of depressive symptoms, and especially the degree 
of psychomotor retardation, influences the amount 
of change in pain perception is not supported. One 
reason for this discrepancy might be that these re-
lationships appear only when different diagnostic 
subgroups of depression are grouped together. In the 
present study, only patients with the diagnosis of 
major depression and a considerable degree of de-
pressive symptomatology were investigated. Taken 
together, these findings suggest that, from a certain 
degree of disease severity on, pain perception is 
affected in an all-or-nothing fashion. 
Naloxone did not differ from placebo in its effect 
on the pain thresholds either in the depressive pa-
tients or in the healthy controls. Therefore, the 
elevated thresholds of the patients were probably 
not caused by a naloxone-sensitive analgesic mech-
anism or, as far as this can be proven by the appli-
cation of an antagonist, by an excess activity of 
endogenous opioids. In this respect, the finding in 
the present study is similar to our earlier finding in 
patients with anorexia nervosa and bulimia nervosa, 
where the elevated pain thresholds also could not 
be normalized by the same dosage of naloxone (26, 
32). Whether this constitutes a neurobiological sim-
ilarity between these disorders, especially between 
depression and bulimia nervosa, remains to be clar-
ified. Several neurotransmitter and neurohormone 
systems are involved in forms of analgesia that are 
not reversible by naloxone; in this context, these 
systems represent potential candidates for causation 
(33). 
Same comments on the effect of naloxone on pain 
perception in nonclinical samples are in order. Nal-
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oxone (5 mg IV) had no effect on the pain thresholds 
of the healthy controls. We and several other authors 
had made similar observations in earlier studies (26, 
34-36). Buchsbaum et al. (37) presented some ten-
tative data showing an increased pain sensitivity 
after a dose of 2 mg, but only in healthy controls 
classified as pain-insensitive. With respect to pain-
evoked cerebral potentials, Bromm et al. (35) ob-
served an amplitude increase after an oral dose of 
32 mg, and Davis et al. (36) observed a shortening of 
latencies after 2 mg IV. Hence, the evidence for 
systematic changes in pain perception in humans 
after naloxone administration has been weak. 
Whereas naloxone had no impact on pain percep-
tion, it seemed to affect the thermal thresholds (the 
cold threshold strongly and the warmth threshold 
slightly) in the depressive patients. Under placebo 
the patients showed a reduction in thermal sensitiv-
ity during repeated testing. We think that a decrease 
in sustained attention or vigilance, which is more 
likely to occur in depressives than in healthy per-
sons (38-40), might have been responsible for this 
effect. (The thermal thresholds were determined by 
applying weak, affectively neutral stimuli, which 
always started from sub-threshold levels and were 
therefore most susceptible to changes in attention 
or vigilance.) Naloxone, which has been found to 
have beneficial short-term effects on some atten-
tional processes (41, 42), might have counteracted 
the reduction in thermal sensitivity during repeated 
testing. However, a replication is necessary before 
any definite conclusions can be drawn. 
In summary, the pain threshold was elevated in 
our depressive patients, and this was not due to a 
generalized somatosensory deficit. Thus, the diag-
nosis of major depression according to DSM-III-R 
appeared to identify a group of patients with hypal-
gesic changes. There were no relationships between 
various aspects of depression (depressive mood, 
functional impairment, anxiety, cognitive and psy-
chomotor changes, etc.) and pain thresholds in this 
distinct group of patients. Naloxone did not differ 
from placebo in its effect on pain thresholds in either 
the depressive patients or the healthy controls. 
Therefore, an opioidergic causation of the pain 
threshold elevation is unlikely. 
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